Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 8/17 cls
Array BioPharma Inc. (NASDAQ:ARRY) Leerink Howard Liang Upgrade Outperform (from market perform) 21% $5.50
Liang also raised his target to $8 from $4 on "promising" Phase II data for MEK inhibitors selumetinib and MEK126 (formerly ARRY-162). In May, Array reported Phase II data in patients with mutant K-Ras(KRAS)

Read the full 754 word article

User Sign In